Citoqueratina 18 como un biomarcador emergente para el diagnóstico no invasivo de la esteatohepatitis no alcohólica
DOI:
https://doi.org/10.62305/biosana.v5i5.840Palabras clave:
Enfermedad del hígado graso no alcohólico, esteatohepatitis no alcohólica, queratina-18, biomarcadoresResumen
La citoqueratina 18 (CK-18) es una proteína del citoesqueleto presente en los hepatocitos, cuyo estudio ha cobrado relevancia clínica como posible biomarcador no invasivo para el diagnóstico de la esteatohepatitis no alcohólica. Se realizó una revisión bibliográfica cuyo objetivo fue analizar el valor diagnóstico de la citoqueratina 18 como un biomarcador no invasivo para la esteatohepatitis no alcohólica. La variedad de estudios revisados evidencia que la CK-18 tiene utilidad diagnóstica para la detección de EHNA, al analizarla en conjunto con otros biomarcadores inflamatorios; sin embargo, no existen valores estandarizados de referencia de la CK-18, lo que dificulta su interpretación clínica. Se concluye que la CK-18 adquiere un valor diagnóstico superior cuando se emplea como parte de paneles no invasivos, contribuyendo a un diagnóstico más preciso y temprano de la esteatohepatitis no alcohólica.
Descargas
Citas
Zhang H, Rios RS, Boursier J, Anty R, Chan WK, George J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-Alcoholic steatohepatitis risk diagnosis: An international registry study. Chin Med J (Engl) [Internet]. 2023 Feb 5 [cited 2025 Sep 1];136(3):341–50. Available from: https://pubmed.ncbi.nlm.nih.gov/36848175/
Alaa H, Mahmoud A, Dalia S, Somaia SE, Sheren Y, Esmat M. Value of Cytokeratin-18 as a non-invasive diagnostic biomarker of nonalcoholic steatohepatitis (NASH). Medical Journal of Viral Hepatitis [Internet]. 2019 Apr 1 [cited 2025 Sep 1];3.2(2):65–74. Available from: https://mjvh.journals.ekb.eg/article_55732.html
Rojas YAO, Cuellar CLV, Barrón KMA, Arab JP, Miranda AL. Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. Ann Hepatol [Internet]. 2022 Nov 1 [cited 2025 Sep 1];27(6). Available from: https://pubmed.ncbi.nlm.nih.gov/35427804/
Cabrera D, Moncayo-Rizzo J, Cevallos K, Alvarado-Villa G. Waist Circumference as a Risk Factor for Non-Alcoholic Fatty Liver Disease in Older Adults in Guayaquil, Ecuador. Geriatrics 2023, Vol 8, Page 42 [Internet]. 2023 Apr 14 [cited 2025 Sep 10];8(2):42. Available from: https://www.mdpi.com/2308-3417/8/2/42/htm
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord [Internet]. 2022 Dec 1 [cited 2025 Sep 1];22(1):1–9. Available from: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1
Rinella ME, Lazarus J V, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol [Internet]. 2023 [cited 2025 Oct 10];79:1542–56. Available from: https://doi.org/10.1016/j.jhep.2023.06.003
Al-Beltaji Ali, Al-qatati Abeer, Alzaharna Mazen. View of Serum Cytokeratin-18 as a Non-invasive Biomarker and its Association with Biochemical Parameters in the Diagnosis of Non-alcoholic Fatty Liver Disease [Internet]. 2024 [cited 2025 Sep 8]. Available from: https://jjournals.ju.edu.jo/index.php/JMJ/article/view/245/1062
Cañarte Murillo JR, López López LY, Lascano Garcés MO, Guiracocha Franco KN, Morales Toapanta MS. Insuficiencia hepática relacionada con la esteatosis en jóvenes de Ecuador. Arandu UTIC. 2024 Oct 1;11(2):660–77.
Coello Viñán JE, Sánchez-De la Torre ME, Coronel Parra AM, Caicedo Mosquera DS, Sócola Macas RY, Escobar Bautista AR, et al. Factores asociados a esteatosis hepática no alcohólica en pacientes del área rural del cantón Chambo. Revista Eugenio Espejo [Internet]. 2022 Jan 11 [cited 2025 Sep 1];16(1):39–49. Available from: http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&pid=S2661-67422022000100039&lng=es&nrm=iso&tlng=es
López-Sánchez GN, Montalvo-Javé E, Domínguez-Perez M, Antuna-Puente B, Beltrán-Anaya FO, Hidalgo-Miranda A, et al. Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD. Ann Hepatol [Internet]. 2022 Nov 1 [cited 2025 Oct 10];27(6):100756. Available from: https://www.sciencedirect.com/science/article/pii/S1665268122000989?via%3Dihub
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology [Internet]. 2005 Jun 1 [cited 2025 Sep 10];41(6):1313–21. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.20701
Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, et al. Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastro Hep Advances [Internet]. 2024 Jan 1 [cited 2025 Oct 9];3(8):1120–8. Available from: https://pubmed.ncbi.nlm.nih.gov/39533978/
Liu Z, Ren Q, Mu H, Zeng Y, An Z, He H. Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD. BMC Gastroenterol [Internet]. 2024 Dec 1 [cited 2025 Oct 10];24(1):1–10. Available from: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03258-z
Pagano S, Bakker SJL, Juillard C, Dullaart RPF, Vuilleumier N. Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease. 2023 [cited 2025 Oct 8]; Available from: https://doi.org/10.3390/biom13071128
de Alteriis G, Pugliese G, Di Sarno A, Muscogiuri G, Barrea L, Cossiga V, et al. Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage. Int J Mol Sci [Internet]. 2023 Jul 1 [cited 2025 Oct 10];24(13):10885. Available from: https://www.mdpi.com/1422-0067/24/13/10885/htm
Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Julia Brosnan M, et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One [Internet]. 2020 Sep 1 [cited 2025 Sep 20];15(9):e0238717. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238717
Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, et al. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. Hepatol Commun [Internet]. 2022 Aug 1 [cited 2025 Sep 21];6(8):1987–99. Available from: https://pubmed.ncbi.nlm.nih.gov/35485207/
Choi SJ, Yoon S, Kim KK, Kim D, Lee HE, Kim KG, et al. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease. Diabetes Metab J [Internet]. 2024 Jul 1 [cited 2025 Sep 22];48(4):740–51. Available from: http://e-dmj.org/journal/view.php?doi=10.4093/dmj.2023.0189
Zheng KI, Liu WY, Pan XY, Ma HL, Zhu PW, Wu XX, et al. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Res Care [Internet]. 2020 Mar 4 [cited 2025 Sep 24];8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32139603/
Zhang X, Zheng MH, Liu D, Lin Y, Song SJ, Chu ESH, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab [Internet]. 2025 Jan 7 [cited 2025 Sep 22];37(1):59-68.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/39500327/
Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M, et al. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. World J Hepatol [Internet]. 2021 Dec 27 [cited 2025 Sep 22];13(12):2179–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35070018
Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, et al. Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. PLoS One [Internet]. 2014 Mar 17 [cited 2025 Nov 6];9(3):e91987. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091987
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Revista Científica de Salud BIOSANA
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
